Real‐world evidence of brigatinib as second‐line treatment after crizotinib for ALK + non‐small cell lung cancer using South Korean claims data (K‐ AREAL )
Cancer Medicine · 2024
DOI: 10.1002/cam4.70030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Jeong Eun Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonology, Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Crizotinib, Lung Neoplasms, Organophosphorus Compounds. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceuticals Korea Co., Ltd.
Abstract (Originalsprache)
Purpose
There is a lack of real‐world data in Asian populations for brigatinib, a next‐generation anaplastic lymphoma kinase (ALK) inhibitor for patients with non‐small cell lung cancer (NSCLC). This study analysed real‐world outcomes and dosing patterns for brigatinib in patients with crizotinib‐refractory ALK + NSCLC in South Korea.
Methods
This retrospective, non‐interventional, cohort study used South Korean Health Insurance and Review Assessment claims data for adults with ALK+ NSCLC who initiated brigatinib between 19 April 2019 and 31 March 2021 after receiving prior crizotinib. Patients' characteristics, time to discontinuation (TTD), time to dose reduction, overall survival (OS) and treatment adherence were assessed.
Results
The study included 174 patients (56.9% male; 27.0% with a history of brain metastases). Median duration of prior crizotinib was 17 (range 0.3–48) months. Median follow‐up after brigatinib initiation was 18 (range 0–34) months. Overall, 88.5% of patients received full‐dose brigatinib (180 mg/day) and 93.1% of patients were adherent (proportion of days covered ≥0.8). The median TTD was 24.9 months (95% CI 15.2–not reached). The probability of continuing treatment was 63.2% at 1 year and 51.5% at 2 years. The probability of continuing at full or peak dose was 79.7% at 1 year and 75.6% at 2 years. Median OS was not reached. The 2‐year OS rate was 68.7%.
Conclusions
In this first nationwide retrospective study using national insurance claim data, brigatinib demonstrated real‐world clinical benefit as second‐line treatment after prior crizotinib in ALK + NSCLC patients in South Korea.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonology, Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Korea.
- Division of Big Data Science, Korea University, Sejong, Korea.
- School of Pharmacy, Sungkyunkwan University, Suwon, Korea.
- Takeda Pharmaceuticals Korea Co., Ltd., Seoul, Korea.
ORCID-Profile: Jeong Eun Lee
Förderung
- Takeda Pharmaceuticals Korea Co., Ltd
Zitieren
APA
Lee, J. E., Nam, J. H., Kwon, S. H., Kim, B. K., & Ha, S. M. (2024). Real‐world evidence of brigatinib as second‐line treatment after crizotinib for ALK + non‐small cell lung cancer using South Korean claims data (K‐ AREAL ). Cancer Medicine. https://doi.org/10.1002/cam4.70030
Vancouver
Lee JE, Nam JH, Kwon SH, Kim BK, Ha SM. Real‐world evidence of brigatinib as second‐line treatment after crizotinib for ALK + non‐small cell lung cancer using South Korean claims data (K‐ AREAL ). Cancer Medicine. 2024. doi:10.1002/cam4.70030
BibTeX
@article{Lee2024,
author = {Lee, Jeong Eun and Nam, Jin Hyun and Kwon, Sun Hong and Kim, Bo Kyung and Ha, Seung Min},
title = {Real‐world evidence of brigatinib as second‐line treatment after crizotinib for ALK + non‐small cell lung cancer using South Korean claims data (K‐ AREAL )},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70030}
}
EUVIMED